阿达普特生物科技
ADPT
24.02
-1.56
-6.10%
阿达普特生物科技
US · ADPT
#2184 按市值排名
上市于 2019
24.02
-1.56
-6.10%
实时 - 追踪5344个代码 - 心跳于372秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 99.44% -0.01pp
- 机构数量
- 363 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund66.82%
Hedge Fund26.20%
Individual/Insider2.58%
Private Company2.34%
Public Company1.94%
Insurance Company0.82%
VC/PE Fund0.76%
Government Pension Fund0.32%
Bank/Investment Bank0.16%
主要股东 截至 2026-06-30
Viking Global Investors LP
18.79% · 29.99M 股
BlackRock
9.49% · 15.14M 股
Vanguard Capital Management, LLC
4.60% · 7.34M 股
Wellington Management Group
3.70% · 5.91M 股
Vanguard Portfolio Management, LLC
3.43% · 5.48M 股
D. E. Shaw & Co., L.P.
2.90% · 4.63M 股
T. Rowe Price Group, Inc.
2.79% · 4.44M 股
Westfield Capital Management Company, L.P.
2.67% · 4.27M 股
Geode Capital Management, LLC
2.28% · 3.64M 股
State Street Global Advisors
2.17% · 3.46M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 0次买入 · 50次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Viking Global Investors LP | -- | 18.79% |
| Chad Robins | Chairperson & CEO | 0.95% |
| Harlan Robins | Co-Founder & CSO | 0.51% |
| Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | 0.25% |
| Julie Rubinstein | President | 0.24% |
| Kyle Piskel | VP & Principal Accounting Officer | 0.16% |
| Francis Lo | Chief Human Resources Officer | 0.14% |
| Sharon Benzeno | Chief Commercial Officer of Immune Medicine | 0.14% |
| Peter Neupert | Lead Independent Director | 0.08% |
| Katey Owen | Independent Director | 0.04% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Julie Rubinstein | President | Derivative Exercise and Sale | -35,643 | $12.14–29.67 |
| 2026-09-30 | Julie Rubinstein | President | Intent to Sell (Form 144) | -379,777 | $28.90 |
| 2026-09-30 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -26,792 | $3.99–28.61 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Automatic Disposition | -9,846 | $28.02–28.57 |
| 2026-09-15 | Francis Lo | Chief Human Resources Officer | Derivative Exercise and Sale | -105,560 | $3.99–28.02 |
| 2026-09-14 | Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | Automatic Disposition | -1,195 | $27.00 |
| 2026-08-30 | Katey Owen | Independent Director | Other Disposition | -12,539 | -- |
| 2026-08-25 | Katey Owen | Independent Director | Open Market Disposition | -9,615 | $26.00 |
| 2026-08-19 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -402,160 | $25.44 |
| 2026-08-18 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -215,632 | $25.49 |
| 2026-08-17 | Robert Hershberg | Independent Director | Open Market Disposition | -15,664 | $24.41 |
| 2026-08-17 | Robert Hershberg | Independent Director | Derivative Exercise and Sale | -15,000 | $6.32–24.39 |
| 2026-08-17 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -261,044 | $24.56 |
| 2026-08-17 | Chad Robins | Chairperson & CEO | Derivative Exercise and Sale | -600,000 | $6.55–25.57 |
| 2026-08-17 | Chad Robins | Chairperson & CEO | Intent to Sell (Form 144) | -278,676 | $24.56 |
| 2026-08-16 | Peter Neupert | Lead Independent Director | Open Market Disposition | -109,690 | $25.10–25.16 |
| 2026-08-16 | Peter Neupert | Lead Independent Director | Derivative Exercise and Sale | -15,000 | $6.32–25.23 |
| 2026-08-16 | Harlan Robins | Co-Founder & CSO | Intent to Sell (Form 144) | -300,992 | $24.77 |
| 2026-08-16 | Chad Robins | Chairperson & CEO | Intent to Sell (Form 144) | -321,324 | $24.77 |
| 2026-08-09 | Susan Bobulsky | Senior Vice President of Diagnostics - ClonoSEQ | Automatic Disposition | -3,000 | $25.00 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿达普特生物科技 讨论区 0 条评论